Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11552188 | 0.98 | CHRNA7 (0.52) | CHRNA7SIGMAR1DRD2HTR6CYP3A4 | |
| SCHEMBL576814 | 0.81 | LMNA (0.67) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 | |
| SCHEMBL16924853 | 0.81 | LMNA (0.67) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 | |
| SCHEMBL164538 | 0.81 | LMNA (0.67) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 | |
| SCHEMBL385012 | 0.81 | — | — | |
| SCHEMBL576454 | 0.81 | LMNA (0.67) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 | |
| SCHEMBL14480008 | 0.79 | LMNA (0.57) | MAPK1MAPTLMNAMEN1KMT2A | |
| SCHEMBL597189 | 0.78 | CHRNA7 (0.53) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 | |
| SCHEMBL7258870 | 0.78 | LMNA (0.64) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 | |
| SCHEMBL740054 | 0.78 | CHRNA7 (0.58) | CHRNA7SIGMAR1DRD2CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | claimed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | claimed |
| WO-2021034087-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | 주식회사 셀젠텍 | 2021-02-25 | — | — | WO | claimed |
| CN-108341807-B | Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof | 平顶山学院 | 2020-07-28 | — | — | CN | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| CN-105777731-B | The bridged piperazine derivatives and its preparation method and application of Han You oxadiazoles | 山东理工大学 | 2018-10-16 | — | — | CN | claimed |
| CN-108341807-A | Piperazine acidamide compound of the skeleton containing benzodioxan and its preparation method and application | 平顶山学院 | 2018-07-31 | — | — | CN | claimed |
| CN-108003118-A | A kind of posaconazole intermediate 1-（4- hydroxy phenyls）-4-（4- aminophenyls）The preparation process of-piperazine | 张家口市格瑞高新技术有限公司 | 2018-05-08 | — | — | CN | claimed |
| CN-104230915-B | Phenylpiperazine derivatives containing thiazolidinedione and preparation method thereof and purposes | 南京大学 | 2016-08-17 | — | — | CN | claimed |
| CN-105777731-A | Oxadiazole-containing piperazine derivative as well as preparation method and use thereof | 山东理工大学 | 2016-07-20 | — | — | CN | claimed |
| CN-104230915-A | Thiazolidinedione-containing phenylpiperazine derivatives as well as preparation method and applications of thiazolidinedione-containing phenylpiperazine derivatives | NANJING UNIVERSITY OF TECHNOLOGY | 2014-12-24 | — | — | CN | claimed |
| CN-102234267-A | Novel triazole antifungal compounds, and medicinal composition, preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2011-11-09 | — | — | CN | claimed |
| US-4107437-A | SEDATIVES, ANTIARRHYTHMIA AGENTS | PARCOR (FR) | 1978-08-15 | — | — | US | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| US-4493837-A | VASODILATORS, ANALGESICS, NEUROLEPTIC AGENTS | EISAI CO., LTD. (JP) | 1985-01-15 | — | — | US | disclosed |
| US-4147869-A | ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
| US-3997666-A | HYPOTENSIVE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | CHRNA7 4344/4885SIGMAR1 4166/4885DRD2 4416/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | CHRNA7 1832/4885SIGMAR1 4868/4885DRD2 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.